Elanco’s Zenrelia (ilunocitinib) Wins Positive CVMP Opinion, Paving the Way for EU Approval and Market Release Elanco Animal Health Incorporated (NYSE: ELAN) today announces a significant milestone in its ongoing expansion into veterinary care: the Committee for Veterinary Medicinal Products…
mRNA Technology Transfer Programme Moves Into Phase 2.0, Boosting Sustainable Local Vaccine Manufacturing and Global Health Security In parallel with the G20 Health Working Group meeting, global health leaders and stakeholders are gathering in Johannesburg, South Africa, to accelerate the…
Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced a significant new collaboration aimed at strengthening Japan’s role as…
FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®…
Bristol Myers Squibb Highlights Targeted Protein Degradation Advances, Including CELMoD Agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy Bristol Myers Squibb today revealed new and updated data from its growing portfolio of targeted protein degradation programs during…
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers…
Merck Animal Health Wins Positive EU CVMP Opinion for NUMELVI (atinvicitinib) Tablets for Dogs Merck Animal Health, a division of Merck & Co known as MSD Animal Health outside the United States and Canada today announced a significant milestone in…
FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a significant regulatory milestone from the U.S. Food and Drug Administration…
Bayer and Broad Institute Extend Landmark Collaboration to Advance Cardiovascular Genomics and Precision Medicine In a bold continuation of a decade-long scientific alliance, Bayer and the Broad Institute of MIT and Harvard have announced a five-year extension of their ongoing…
Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for an expanded indication of its RNAi drug AMVUTTRA® (vutrisiran). The…
WHO Sounds Alarm on Imminent Collapse of Gaza Health System as Nasser and Al-Amal Hospitals Face Shutdown The World Health Organization (WHO) has issued an urgent warning about the imminent collapse of the healthcare system in the Gaza Strip, emphasizing…
Anne-Catherine Berner Appointed as New Chair of Grifols: A Strategic Move Toward Long-Term Value Creation and Governance Excellence Grifols a global leader in the development of plasma-derived therapies and diagnostic technologies, has announced a key leadership transition following its 2025…